Table 4

HRs for incidence of CVD associated with variability in HbA1c and SBP stratified according to mean HbA1c and SBP levels

	Mean HbA1c<7.0%		Mean HbA1c≥7.0%		Interaction p	Mean SBP<130 mm Hg		Mean SBP≥130 mm Hg		Interaction p
	HR (95% CI)	p Value	HR (95% CI)	p Value	Interaction p	HR (95% CI)	p Value	HR (95% CI)	p Value	Interaction p
Events/patients	37/338		44/294			37/306		44/326
Model 1
HbA1cCV (1SD increment)	1.20 (0.76 to 1.88)	0.44	1.37 (1.00 to 1.87)	0.052		0.99 (0.65 to 1.52)	0.97	1.77 (1.28 to 2.46)	0.0007	0.018
SBPCV (1SD increment)	1.33 (0.97 to 1.81)	0.076	1.30 (0.89 to 1.88)	0.18	0.79	1.59 (1.11 to 2.29)	0.013	1.16 (0.86 to 1.56)	0.34
Model 2
HbA1cVIM (1SD increment)	1.17 (0.83 to 1.66)	0.37	1.38 (0.99 to 1.93)	0.054		0.96 (0.64 to 1.44)	0.85	1.73 (1.25 to 2.38)	0.0009	0.016
SBPVIM (1SD increment)	1.32 (0.97 to 1.80)	0.076	1.31 (0.90 to 1.90)	0.16	0.82	1.59 (1.12 to 2.28)	0.011	1.19 (0.89 to 1.60)	0.25

All models were adjusted for mean HbA1c, mean SBP, number of visits (ln-transformed), age, sex, diabetes duration, BMI, TC/HDL-C, eGFR, baseline smoking status, baseline alcohol intake, baseline use of insulin, and baseline use of antihypertensive agents.
BMI, body mass index; CV, coefficient of variation; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; VIM, variation independent of mean.